Evaluation of dependence and long-term use safety of DaliRasheng (Keweike)

Daridorexant is a new type of dual hypnotic receptor antagonist (DORA), which mainly works by selectively inhibiting wake-promoting neuropeptide receptors ( orexin-1 and orexin-2) to promote sleep without directly acting on GABA receptors. This mechanism of action makes Dalilaysan significantly effective in improving sleep onset and maintaining sleep, while reducing the common risks of tolerance and dependence with traditional sedative-hypnotic drugs. Therefore, from a pharmacological point of view, Dalilaysan has lower dependence, but it still needs to be used under the guidance of a doctor.

In clinical studies, the long-term safety of DaliRasen has been verified to some extent. Multiple Phase II and Phase III clinical trials have shown that the drug can still effectively improve sleep parameters when patients use it continuously for weeks to months, and no obvious drug tolerance or dependence has been observed. Most of the adverse reactions in the study were mild to moderate, including dizziness, drowsiness, dry mouth, etc. The symptoms could resolve spontaneously after stopping the drug. This shows that in the long-term treatment of patients with insomnia, the risk of dependence is significantly lower than that of traditional benzodiazepines.

Although the risk of dependence is low, patients should still follow their doctor's advice when taking dalirasant long-term. First of all, patients should take a fixed dose as prescribed by the doctor, and should not increase the dose on their own to pursue the effect of falling asleep faster; secondly, they should be reviewed regularly to evaluate sleep improvement and possible adverse reactions; finally, for patients with severe liver and kidney damage, respiratory diseases or mental illness, they should use it with caution or adjust the dose to ensure drug safety.

Overall, the dependence of DaliRaxon is low and it is relatively safe for long-term use, but it still requires individualized management. In practical applications, reasonable dosage control, standardized medication time, and regular evaluation of efficacy and safety are the keys to ensuring long-term use of DaliRasen. At the same time, patients should combine sleep hygiene guidance, behavioral therapy and other non-drug interventions to improve the overall effect of treatment and reduce the risk of long-term medication.

Reference materials:https://www.drugs.com/